ASO Practice Guidelines Series: Surgical Management of Gastrointestinal (Midgut) Neuroendocrine Neoplasms. Ann Surg Oncol 2024 Mar;31(3):1704-1713
Date
01/04/2024Pubmed ID
38167813DOI
10.1245/s10434-023-14802-8Scopus ID
2-s2.0-85181198604 (requires institutional sign-in at Scopus site) 1 CitationAbstract
Gastrointestinal midgut neuroendocrine neoplasms (NENs) are a heterogeneous group of uncommon malignancies. For well-differentiated NENs, known as neuroendocrine tumors (NETs), surgery is a cornerstone of management in localized and metastatic disease. Because of heterogeneous tumor behaviour, association with endocrine syndrome, and prognosis, the management of NETs must be individualized to all these factors in addition to the primary site. With the fast pace of advancement in the field, both for therapies and understanding of tumoral etiology and behaviour, it is important for surgical oncologists to remain updated on guidelines recommendations and suggested treatment pathways. Those guidelines provide important guidance for management of NETs but are largely based on expert opinions and interpretation of retrospective evidence. This article reviews highlights of most recent practice guidelines for midgut (gastric, duodenal, small intestinal, and appendiceal) NETs.
Author List
Hallet J, Clarke CNAuthor
Callisia N. Clarke MD Chief, Associate Professor in the Surgery department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Gastrointestinal NeoplasmsHumans
Intestinal Neoplasms
Neuroendocrine Tumors
Pancreatic Neoplasms
Prognosis
Retrospective Studies
Stomach Neoplasms
